Moderna’s mRNA flu vaccine more effective than current SOC

The FDA previously refused to review Moderna's mRNA-1010 for flu but has u-turned on this decision. The FDA previously refused to review mRNA-1010 but has u-turned on this decision. Moderna is awaiting and FDA decision on the vaccine. Credit: Stig Alenas / Shutterstock.com Moderna’s mRNA flu vaccine has proved to be more effective than a standard flu vaccine in a Phase III trial. In the study (NCT06602024), which enrolled more than 40,000 adults aged 50 and above, Moderna’s mRNA-1010 was 26.6% more effective compared to a comparator vaccine, which was GSK’s Fluarix or Alpharix. LOA and PTSR Model MRNA-1083…

Source: Clinical Trials Arena